Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isatuximab + RVd Induction and Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma
NCT03617731Phase 3Active, not recruiting
- Start
- Oct 2018
- Primary completion
- Jun 2028
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of isatuximab in multiple myeloma (MM) (4 arms). Primary endpoints: Minimal Residual Disease negativity after induction at 18 weeks and Progression-Free Survival after second randomization up to 3 years. Started Oct 2018; status: active, not recruiting.
02
Drugs
isatuximab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03617731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03617731.